Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
A Trial to Evaluate the Effect of LEO 152020 on the Heart of Healthy People
- Conditions
- Healthy VolunteersCardiac Repolarisation
- Interventions
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- JW Pharmaceutical
- Target Recruit Count
- 28
- Registration Number
- NCT05508776
- Locations
- 🇬🇧
LEO Investigational Site, Leeds, United Kingdom
A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy Participants
- Conditions
- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and MenHot FlashesHealthy Volunteers
- Interventions
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 51
- Registration Number
- NCT05481528
- Locations
- 🇩🇪
NUVISAN GmbH Neu-Ulm, Neu-Ulm, Bayern, Germany
An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics
- Conditions
- QTc IntervalPharmacokinetics
- Interventions
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- Usona Institute
- Target Recruit Count
- 60
- Registration Number
- NCT05478278
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Inc, Overland Park, Kansas, United States
Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment
- Conditions
- Tuberculosis, Pulmonary
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 620
- Registration Number
- NCT05454345
Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis
- Conditions
- Endocarditis Infective
- Interventions
- Drug: Fusidic Acid Only Product in Oral Dose FormDrug: Fusidic Acid Only Product in Parenteral Dose Form
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Fundacion Clinic per a la Recerca Biomédica
- Target Recruit Count
- 360
- Registration Number
- NCT05398679
- Locations
- 🇪🇸
Hospital Virgen de la Macarena, Sevilla, Andalucía, Spain
🇪🇸Hospital Virgen del Rocío, Sevilla, Andalucía, Spain
🇪🇸Parc Taulí Hospital Universitari, Sabadell, Barcelona, Spain
A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
- Conditions
- COPD Exacerbation Acute
- Interventions
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 140
- Registration Number
- NCT05400369
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, China
🇨🇳West China Hospital Sichuan University, Chengdu, China
🇨🇳Qilu Hospital of Shandong University, Jinan, China
A Thorough QT Study of Aticaprant (JNJ-67953964) in Healthy Adult Participants
- Conditions
- Healthy
- Interventions
- Drug: Aticaprant Supratherapeutic DoseDrug: Aticaprant Therapeutic DoseDrug: Placebo
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT05387759
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 48
- Registration Number
- NCT05355935
- Locations
- 🇺🇸
USA001, Madison, Wisconsin, United States
Dropless Pars Plana Vitrectomy Study
- Conditions
- Rhegmatogenous Retinal Detachment
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Massachusetts Eye and Ear Infirmary
- Target Recruit Count
- 168
- Registration Number
- NCT05331664
- Locations
- 🇺🇸
Massachusetts Eye and Ear, Boston, Massachusetts, United States
A Study of Soticlestat in Healthy Adults To Evaluate the Effect on QTc Interval
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Takeda
- Registration Number
- NCT05309902
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.